Astellas | Mission First
Curator24 created a multi-layered campaign to inspire and motivate the national sales team for XOSPATA® (gilteritinib), the first FDA-approved targeted therapy for relapsed or refractory FLT3m+ acute myeloid leukemia (AML).
Curator24 created a multi-layered campaign to inspire and motivate the national sales team for XOSPATA® (gilteritinib), the first FDA-approved targeted therapy for relapsed or refractory FLT3m+ acute myeloid leukemia (AML).